Press release
Progressive Familial Intrahepatic Cholestasis (PFIC) Market on the Verge of Extraordinary Growth During the Forecast Period (2023-32) | Vivet Therapeutics (VTX-803), Mirum Pharmaceuticals (Maralixibat)
DelveInsight's "Progressive Familial Intrahepatic Cholestasis (PFIC) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Progressive Familial Intrahepatic Cholestasis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The market report covers emerging drugs, treatment practices, market share of individual Progressive Familial Intrahepatic Cholestasis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Progressive Familial Intrahepatic Cholestasis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Progressive Familial Intrahepatic Cholestasis (PFIC): An Overview
According to the National Institute of Health (NIH), Progressive Familial Intrahepatic Cholestasis (PFIC) is a disorder that causes progressive liver disease, which typically leads to liver failure in which liver cells are unable to secrete a digestive fluid called bile. The buildup of bile in liver cells causes liver disease in affected individuals. The average age at onset is three months, although some patients do not develop jaundice until later, even as late as adolescence. PFIC can progress rapidly and cause cirrhosis during infancy or may progress relatively slowly with minimal scarring into adolescence. Few patients survive into the third decade of life without treatment.
There are mainly three types of PFIC which occur due to mutations in the genes, such as ATP8B1, ABCB11, and ABCB4, which result in development of PFIC1, PFIC2, and PFIC3 respectively. Mutations in these genes lead to a failure of proteins to function normally and thereby cause PFIC in many patients. PFIC usually appears in the first months of life in patients with PFIC1 resulting in characterized by recurrent episodes of jaundice, which become permanent later in the course of the disease. In case of PFIC2, the initial presentation and the evolution seem to become more severe, resulting into permanent jaundice from the first months of life and the rapid appearance of liver failure within the first years of life.
Progressive Familial Intrahepatic Cholestasis (PFIC) Market Key Facts
• As per the Progressive Familial Intrahepatic Cholestasis (PFIC) Organization, PFIC affects about 1 in 100,000 people worldwide with recently discovered new genes, such as TJP2, NRIH4 and MYO5B.
• The United Kingdom-based study titled "Systematic review of progressive familial intrahepatic cholestasis" conducted by Baker et al. found that the incidence of intrahepatic cholestasis was 1 per 18,000 live births. The researchers also referred to a study in which infants and children (2-18 years) with cholestasis were 12-13% with genetically diagnosed PFIC.
• According to a French study by Davit-Spraul et al., titled "Progressive familial intrahepatic cholestasis", highlighted that the estimated incidence varies between 1 per 50,000 and 1 per 100,000 births in the PFIC patients. It was also found that PFIC1 and PFIC2 represented two out of three cases of total PFIC, whereas PFIC3 was one case per three cases.
• BYLVAY (odevixibat) is the only FDA approved drug available to meet the demands of the patients. Overall, the 7MM PFIC therapeutics market is further expected to increase via efficient research and development.
• Of the emerging therapies for PFIC, the key players include Mirum Pharmaceuticals (Maralixibat), and Vivet Therapeutics.
Get a Detailed Overview of the Evolving Progressive Familial Intrahepatic Cholestasis Market Trends @
https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Progressive Familial Intrahepatic Cholestasis (PFIC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Progressive Familial Intrahepatic Cholestasis therapies in the market. It also provides a detailed assessment of the Progressive Familial Intrahepatic Cholestasis market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete details of the market trend for each marketed Progressive Familial Intrahepatic Cholestasis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Discover How the Progressive Familial Intrahepatic Cholestasis Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Progressive Familial Intrahepatic Cholestasis (PFIC) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Progressive Familial Intrahepatic Cholestasis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.
The Report Covers the Progressive Familial Intrahepatic Cholestasis Epidemiology Segmented as -
• Prevalent Population of PFIC in the 7MM [2019-2032]
• Type-specific Prevalent Population of PFIC in the 7MM [2019-2032]
• Diagnosed and Treatable Cases of PFIC in the 7MM [2019-2032]
Get Key Insights Into the Evolving Progressive Familial Intrahepatic Cholestasis Epidemiology Trends @
https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Progressive Familial Intrahepatic Cholestasis (PFIC) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Progressive Familial Intrahepatic Cholestasis market or expected to be launched during the study period. The analysis covers the market share by Progressive Familial Intrahepatic Cholestasis drugs, patient uptake by therapies, and sales of each drug.
The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.
The report also covers the Progressive Familial Intrahepatic Cholestasis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Explore More About Ongoing Pipeline Development Activities in the Progressive Familial Intrahepatic Cholestasis Market @
https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Progressive Familial Intrahepatic Cholestasis (PFIC) Therapeutics Assessment
Currently, the market of PFIC has BYLVAY (odevixibat) as the only FDA-approved drug. Changes in the diet, medicines, and surgical treatments can also reduce the effects and complications of the condition. The treatment, which is generally symptomatic, involves observation of the expert physicians depending on the features and severity of the condition and its effects.
There are certain off-label drugs for the symptomatic treatment for PFIC, such as ursodeoxycholic acid (UDCA), cholestyramine, rifampicin, phenobarbital, antihistaminic agents, ondansetron, steroids, propofol, and carbamazepine.
Several major pharma and biotech companies are developing therapies for Progressive Familial Intrahepatic Cholestasis (PFIC). Currently, Mirum Pharmaceuticals is leading the therapeutics market with its Progressive Familial Intrahepatic Cholestasis (PFIC) drug candidates in the most advanced stage of clinical development.
Leading Companies in the Progressive Familial Intrahepatic Cholestasis (PFIC) Therapeutics Market Include
• Mirum Pharmaceuticals
• Vivet Therapeutics
And Many Others
Emerging and Marketed Progressive Familial Intrahepatic Cholestasis (PFIC) Therapies Covered in the Report Include
• VTX-803: Vivet Therapeutics
• Maralixibat: Mirum Pharmaceuticals
And Many More
Learn More About the Emerging Therapies and key Companies in the Progressive Familial Intrahepatic Cholestasis Therapeutics Market @
https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Progressive Familial Intrahepatic Cholestasis Competitive Intelligence Analysis
4. Progressive Familial Intrahepatic Cholestasis Market Overview at a Glance
5. Progressive Familial Intrahepatic Cholestasis Background and Overview
6. Progressive Familial Intrahepatic Cholestasis Patient Journey
7. Progressive Familial Intrahepatic Cholestasis Epidemiology and Patient Population
8. Progressive Familial Intrahepatic Cholestasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Progressive Familial Intrahepatic Cholestasis Unmet Needs
10. Key Endpoints of Progressive Familial Intrahepatic Cholestasis Treatment
11. Progressive Familial Intrahepatic Cholestasis Marketed Products
12. Progressive Familial Intrahepatic Cholestasis Emerging Therapies
13. Progressive Familial Intrahepatic Cholestasis Seven Major Market Analysis
14. Attribute Analysis
15. Progressive Familial Intrahepatic Cholestasis Market Outlook (7 major markets)
16. Progressive Familial Intrahepatic Cholestasis Access and Reimbursement Overview
17. KOL Views on the Progressive Familial Intrahepatic Cholestasis Market.
18. Progressive Familial Intrahepatic Cholestasis Market Drivers
19. Progressive Familial Intrahepatic Cholestasis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/progressive-familial-intrahepatic-cholestasis-pfic-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research
Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices
Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology
Other Trending Healthcare Reports by DelveInsight
Metrorrhagia Market
https://www.delveinsight.com/report-store/metrorrhagia-market
Dysfunctional Uterine Bleeding Market
https://www.delveinsight.com/report-store/dysfunctional-uterine-bleeding-market
Status Epilepticus Market
https://www.delveinsight.com/report-store/status-epilepticus-market
Brain Hemorrhage Market
https://www.delveinsight.com/report-store/brain-hemorrhage-market
Congenital Adrenal Hyperplasia Market
https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market
Ductal Carcinoma in Situ Market
https://www.delveinsight.com/report-store/ductal-carcinoma-in-situ-market
Electroencephelographs (EEG) Pipeline Insight
https://www.delveinsight.com/report-store/electroencephelographs-eeg-pipeline-insight-and-competitive-landscape
Spinal Decompression/Traction Devices Market
https://www.delveinsight.com/report-store/spinal-decompression-traction-devices-market
Bronchopulmonary Dysplasia Market
https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
Drug Hypersensitivity Market
https://www.delveinsight.com/report-store/drug-hypersensitivity-market
Familial Chylomicronemia Syndrome (FCS) Market
https://www.delveinsight.com/report-store/familial-chylomicronemia-syndrome-market
Implantable Infusion Pumps Market
https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
Postmyocardial Infarction Syndrome Market
https://www.delveinsight.com/report-store/postmyocardial-infarction-syndrome-market
Surgery and Radiation Therapy in Brain Cancer Market
https://www.delveinsight.com/report-store/surgery-and-radiation-therapy-in-brain-cancer-market
Acute ischemic stroke (AIS) Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
Acute On Chronic Liver Failure (ACLF) Market
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
Biliary Tract Cancers (BTCs) Market
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
Gene Therapy for Ocular Rare Disease Market
https://www.delveinsight.com/report-store/gene-therapy-for-ocular-rare-disease-market
Hemophagocytic Lymphohistiocytosis Market
https://www.delveinsight.com/report-store/hemophagocytic-lymphohistiocytosis-market
Staphylococcus Aureus Infection Market
https://www.delveinsight.com/report-store/staphylococcus-aureus-infection-market
Treatment-Resistant Hypertension Market
https://www.delveinsight.com/report-store/treatment-resistant-hypertension-market
Urticaria Or Hives Market
https://www.delveinsight.com/report-store/urticaria-or-hives-market
Acute Heart failure Market
https://www.delveinsight.com/report-store/acute-heart-failure-ahf-market
Bowen's Disease Market
https://www.delveinsight.com/report-store/bowens-disease-market
Contrast-Induced Nephropathy Market
https://www.delveinsight.com/report-store/contrast-induced-nephropathy-market
Delirium Market
https://www.delveinsight.com/report-store/delirium-market
Dry AMD MarketEGFR Inhibitors-Induced Skin Disorders Market
https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market
Excessive Daytime Sleepiness (EDS) Market
https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market
Gene and Cell Therapies Targeting CNS Disorders Market
https://www.delveinsight.com/report-store/gene-and-cell-therapies-targeting-cns-disorders-market
Glioma Market
https://www.delveinsight.com/report-store/glioma-market
Graves Ophthalmopathy Market
https://www.delveinsight.com/report-store/graves-ophthalmopathy-market
H3N2 Infection Market
https://www.delveinsight.com/report-store/h3n2-infection-market
Nontuberculous Mycobacterial (NTM) Infections Market
https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market
Pars Plantis Market
https://www.delveinsight.com/report-store/pars-plantis-market
Pneumothorax Treatment Devices Market
https://www.delveinsight.com/report-store/pneumothorax-treatment-devices-market
Portal Hypertension Market
https://www.delveinsight.com/report-store/portal-hypertension-market
Decompensated Cirrhosis Market
https://www.delveinsight.com/report-store/decompensated-cirrhosis-market
Follicular Lymphoma Market
https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights
Osteochondromas Market
https://www.delveinsight.com/report-store/osteochondromas-market
Hidradenitis Suppurativa Market
https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market
IgG4-Related Disease Market
https://www.delveinsight.com/report-store/igg4-related-disease-market
Lichen Planus Market
https://www.delveinsight.com/report-store/lichen-planus-market
Retinal Vein Occlusion Market
https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
Meniere's Disease Market
https://www.delveinsight.com/report-store/menieres-disease-md-market
Cytokine Release Syndrome Market
https://www.delveinsight.com/report-store/cytokine-release-syndrome-market
Angelman Syndrome Market
https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
Eosinophilic Gastroenteritis (EGE) Market
https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market
Hereditary Transthyretin Amyloidosis (hATTR) Market
https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market
Implantable Infusion Pumps Market
https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
Post-Operative Cataract Surgery Inflammation Market
https://www.delveinsight.com/report-store/post-operative-cataract-surgery-inflammation-market
Antibody-mediated Rejection Market
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Progressive Familial Intrahepatic Cholestasis (PFIC) Market on the Verge of Extraordinary Growth During the Forecast Period (2023-32) | Vivet Therapeutics (VTX-803), Mirum Pharmaceuticals (Maralixibat) here
News-ID: 3257406 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Progressive
Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024 - …
"The progressive multifocal leukoencephalopathy treatment market size has grown rapidly in recent years. It will grow from $1.31 billion in 2023 to $1.46 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to prevalence of underlying conditions, rise in immunosuppressed patients, patient advocacy and awareness, rise of hiv/aids epidemic.
The progressive multifocal leukoencephalopathy treatment market size is…
Progressive Multifocal Leukoencephalopathy Treatment Market Size 2034
DelveInsight's 'Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast - 2034' report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Progressive Multifocal Leukoencephalopathy in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Key Takeaways from the Progressive Multifocal Leukoencephalopathy Market Report
• According to DelveInsight's analysis, the incident cases of PML in the 7MM were approximately 4…
Benefits of Progressive Web App for A Business
Progressive Web Apps (PWAs) offer numerous benefits for businesses seeking to enhance their online presence and improve user experiences. Firstly, PWAs are designed to work seamlessly across various devices and platforms, including desktops, smartphones, and tablets. This cross-platform compatibility ensures that businesses can reach a wider audience without the need for separate native apps for each operating system, thereby reducing development costs and maintenance efforts.
If you are planning to grow…
Seminar on Progressive Farming
Shri Venkateshwara University/VGI Meerut in collaboration with Bhartiya Kisan Union (Meerut Division) is organizing a 1 day seminar on Progressive farming & farmer the foundation of development on Nov 3rd.In this seminar, the National Organization Minister of All India Farmer's Organization Mr Dinesh Kulkarni, Padamshree Mr Bharat Bhushan Tyagi, & the State Agriculture Minister Mr Baldev Singh Aulakh will take part.Apart from these renowned agriculture scientists, environmentalists, bureaucrats & 400…
Progressive Supranuclear Palsy Headed Toward Cure
Progressive supranuclear palsy (PSP) is a brain disorder which impacts vision, cognition, movement, and speech. This disease results in weakness by affecting certain parts of the brain above the cell clusters, known as nuclei (supranuclear), which are involved in controlling eye movements. It usually manifests in mid-to late adulthood, and the survival rate of people suffering from PSP is five to nine years after the disease first appears. It is…
Progressive Personnel rebrands to Progressive Travel Recruitment
Global travel and hospitality recruitment leader, Progressive Personnel, this month re-emerges as Progressive Travel Recruitment with a fresh new look and a new website under the new URL – www.progressivetravelrecruitment.com – with enhanced job search capability.
Progressive Travel Recruitment’s competitive edge, however, remains – a dedicated team of specialist travel recruiters, who have themselves worked in the industry and understand intimately the needs of travel companies and travel candidates, and…
